Quinone‑Related Drug‑Induced Hemolysis
Overview
Quinone‑related drug‑induced hemolysis is a form of acquired hemolytic anemia that occurs when certain medications containing a quinone moiety (e.g., dapsone, primaquine, nitrofurantoin, chloroquine, and some chemotherapeutic agents) generate oxidative stress that damages red blood cells (RBCs). The condition is most common in individuals with an underlying deficiency of the enzyme glucose‑6‑phosphate dehydrogenase (G6PD), which protects RBCs from oxidative injury.
Who it affects: While anyone taking a quinone‑containing drug can theoretically develop hemolysis, >95 % of reported cases occur in people with G6PD deficiency—a hereditary enzymatic disorder affecting an estimated 400 million people worldwide, with higher prevalence in Africa, the Middle East, Southeast Asia, and among Mediterranean ancestry populations [1][2].
Prevalence: In the United States, G6PD deficiency affects about 1–2 % of the overall population and up to 10–14 % of African‑American males. Among these individuals, the reported incidence of hemolysis after exposure to a quinone drug ranges from 5–30 % depending on the drug dose and duration [3]. Worldwide, quinone‑related hemolysis accounts for a small fraction of drug‑induced anemia cases, but it remains a leading cause of preventable hemolysis in regions where G6PD deficiency is common.
Symptoms
Symptoms can appear within hours to a few days after drug exposure and vary with the severity of hemolysis.
- Fatigue & weakness: Due to reduced oxygen‑carrying capacity.
- Pallor: Noticeable especially in the conjunctivae, nail beds, and mucous membranes.
- Jaundice: Yellowing of the skin and sclera caused by elevated bilirubin.
- Dark urine (hemoglobinuria): Tea‑colored urine indicates free hemoglobin excreted by the kidneys.
- Back or flank pain: May signal renal involvement.
- Rapid heart rate (tachycardia) & shortness of breath: Compensatory response to anemia.
- Headache or dizziness: Result of decreased cerebral oxygenation.
- Fever: Can be a sign of severe hemolysis or secondary infection.
- Splenomegaly: An enlarged spleen may be palpable in chronic or severe cases.
- Chest pain: Rare but possible in severe anemia or when cardiac demand increases.
Causes and Risk Factors
Medications with quinone structures
- Antimalarials: Primaquine, tafenoquine, chloroquine.
- Antibiotics: Dapsone, nitrofurantoin, sulfonamides with quinone metabolites.
- Chemotherapeutics: Anthracyclines (e.g., doxorubicin), mitomycin‑C.
- Others: Phenazopyridine, quinidine, certain NSAIDs with quinone‑like metabolites.
Underlying enzyme deficiency
The primary risk factor is G6PD deficiency. The enzyme provides NADPH, which keeps glutathione in its reduced form—critical for neutralizing reactive oxygen species. When G6PD activity is low, oxidative drugs cause RBC membrane damage, leading to intravascular and extravascular hemolysis.
Additional risk factors
- Male sex – G6PD is X‑linked; males are more frequently affected.
- Recent infections or illnesses (e.g., viral hepatitis) that already increase oxidative stress.
- High‑dose or prolonged therapy with quinone drugs.
- Co‑administration of other oxidative agents (e.g., vitamin C at high doses, naphthalene in mothballs).
- Renal impairment – reduces clearance of hemoglobin and increases risk of kidney injury.
Diagnosis
Clinical suspicion
Physicians consider drug‑induced hemolysis when a patient on a quinone medication develops anemia with a rapid drop in hemoglobin (≥2 g/dL) and accompanying signs of hemolysis.
Laboratory tests
- Complete blood count (CBC): Low hemoglobin/hematocrit, often with reticulocytosis (↑ reticulocyte count).
- Peripheral smear: Bite cells, Heinz bodies (after supravital staining), and spherocytes.
- Lactate dehydrogenase (LDH): Elevated due to cell lysis.
- Indirect bilirubin: Increased as hemoglobin is broken down.
- Haptoglobin: Decreased or undetectable because it binds free hemoglobin.
- Urinalysis: Positive for blood on dipstick but no RBCs on microscopy (hemoglobinuria).
- G6PD assay: Quantitative enzyme activity test; recommended after the acute hemolytic episode resolves to avoid false‑normal results.
Additional investigations (if needed)
- Serum creatinine and electrolytes – assess renal function.
- Coombs (direct antiglobulin) test – usually negative in drug‑induced oxidative hemolysis, helps rule out immune hemolytic anemia.
- Genetic testing – sometimes performed for family counseling.
Treatment Options
Immediate measures
- Discontinue the offending drug: The most critical step; hemolysis typically halts within 24–48 hours after cessation.
- Hydration: Intravenous (IV) isotonic fluids (e.g., normal saline) to maintain urine output ≥1 mL/kg/h and reduce risk of pigment nephropathy.
- Transfusion: Packed red blood cells (PRBC) for symptomatic anemia (Hb < 7–8 g/dL) or if there is cardiovascular compromise.
Pharmacologic support
- Folinic acid (leucovorin): May hasten recovery in dapsone‑induced hemolysis by providing reduced folate for RBC regeneration.
- Corticosteroids: Not routinely indicated, but sometimes used if an immune component is suspected.
- Erythropoiesis‑stimulating agents (ESAs): Considered in chronic cases where repeated exposures are unavoidable.
Renal protection
- Alkalinization of urine (e.g., sodium bicarbonate) in severe hemoglobinuria to prevent tubular precipitation.
- Dialysis if acute kidney injury (AKI) progresses despite conservative measures.
Long‑term management
- Patient education about drug avoidance (see Prevention section).
- Regular monitoring of hemoglobin and renal function for patients who must remain on a quinone drug under specialist supervision.
Living with Quinone‑Related Drug‑Induced Hemolysis
Medication safety
- Carry a list of all current medications, over‑the‑counter products, and supplements.
- Inform every prescriber of your G6PD deficiency status.
- Use allergy‑style “medical alert” bracelets specifying “G6PD deficiency – avoid quinone drugs.”
Nutrition and hydration
- Drink at least 2–3 L of water daily (more if you sweat heavily) to support renal clearance of hemoglobin.
- Maintain a balanced diet rich in iron, folate, and vitamin B12 to aid erythropoiesis after a hemolytic episode.
- Avoid high‑dose vitamin C (>2 g/day) and other strong oxidants unless your physician approves.
Monitoring at home
- Check urine color each morning; dark or tea‑colored urine warrants prompt medical review.
- Track symptoms such as increasing fatigue, shortness of breath, or jaundice.
- Schedule periodic CBCs (every 3–6 months) if you have a history of hemolysis.
When travel or illness is involved
- Plan ahead for malaria prophylaxis: Choose non‑quinone agents (e.g., atovaquone/proguanil, doxycycline) if you are G6PD‑deficient.
- During infections, especially viral (e.g., hepatitis, COVID‑19), avoid self‑medicating with over‑the‑counter quinine‑containing products (e.g., tonic water).
Prevention
- Screening: All newborn males in high‑prevalence regions and any individual before initiating quinone therapy should undergo G6PD testing (quantitative assay).
- Alternative drugs: Whenever possible, select non‑oxidant antibiotics (e.g., ceftriaxone instead of dapsone) or antimalarials (e.g., mefloquine, atovaquone).
- Pharmacist involvement: Pharmacists can flag quinone drugs during dispensing and counsel patients.
- Patient education programs: Community health initiatives in endemic areas have reduced hemolysis rates by >40 % (WHO, 2022) [4].
- Vaccination and infection control: Preventing infections reduces the additive oxidative stress that can precipitate hemolysis.
Complications
- Acute kidney injury (AKI): Free hemoglobin can cause tubular necrosis; up to 10 % of severe cases develop AKI requiring dialysis [5].
- Severe anemia: May lead to cardiac ischemia, heart failure, or stroke, particularly in patients with pre‑existing cardiovascular disease.
- Hyperbilirubinemia & gallstones: Chronic bilirubin elevation can predispose to pigment gallstones.
- Chronic hemolysis: Repeated exposures can cause splenomegaly, iron overload, and folate deficiency.
- Pregnancy complications: Maternal hemolysis can cause fetal hypoxia; careful drug selection is essential.
When to Seek Emergency Care
- Sudden, severe fatigue or weakness with dizziness or fainting.
- Chest pain or shortness of breath that worsens rapidly.
- Dark (tea‑colored) urine combined with a rapid drop in urine output.
- Severe jaundice (yellow skin or eyes) accompanied by fever.
- Rapid swelling of the hands, feet, or abdomen (signs of severe fluid shifts).
- Signs of shock: pale, clammy skin, rapid pulse, low blood pressure.
References
- Mayo Clinic. “G6PD deficiency.” 2023. https://www.mayoclinic.org/...
- World Health Organization. “Global prevalence of G6PD deficiency.” 2022. https://www.who.int/...
- Cleveland Clinic. “Drug‑Induced Hemolytic Anemia.” 2021. https://my.clevelandclinic.org/...
- World Health Organization. “Community strategies to prevent quinone‑related hemolysis in G6PD‑deficient populations.” 2022.
- National Institutes of Health. “Acute kidney injury from hemoglobinuria.” 2020. https://www.ncbi.nlm.nih.gov/...